AlertEdge.io
Single-Ticker Trade Brief
ARE — Alexandria Real Estate Equities Report Date: 2026-08-21 17:30 UTC  |  Sector: Real Estate  |  Rating:
RISK DISCLAIMER: This is an automated breakout signal. Always validate before entering a position.
▲ Breakout Signal — Volume Confirmed

ARE closed above the $53.29 breakout level on 1.62x average volume. ATR-based levels set automatically. Next resistance target: $57.46.

Ticker
ARE
Entry Price
$53.58
Breakout Level
$53.29
Stop Loss
$51.35
TP1 Target
$57.46
TP2 Target
$60.05
Risk / Reward
1 : 1.74
1.62x avg volume
View ARE Chart on TradingView

Key Price Levels

TP1 Target
$57.46
Breakout Level
$53.29
Entry
$53.58
Stop Loss
$51.35

Fundamentals

P/E Ratio
N/A
EPS (TTM)
N/A
Dividend Yield
0%
52-Wk High
N/A
52-Wk Low
N/A
Beta
N/A

Deep Dive Analysis — Claude Sonnet

ALERTEDGE TRADE BRIEF — ARE (Alexandria Real Estate Equities)

Generated by AlertEdge.io

SETUP

ARE broke above the $53.29 resistance level on 1.62x average volume, closing at $53.58 with a strong intraday range from $51.87 to $54.00. The bar shows buyers absorbing early weakness and pushing through the breakout level, suggesting genuine demand rather than a fake-out. Price closed near session highs, a constructive sign. TP1 sits at $57.46 with TP2 at $60.05, offering a 1:1.74 risk/reward against a $51.35 stop.

CATALYSTS

Q2 results are the immediate driver. FFO beat estimates, revenues topped expectations, and leasing momentum improved alongside better rental rates — all core metrics for a life science REIT. This fundamental beat gives the technical breakout some teeth. Options market activity suggests elevated expectations for further price movement. Life science real estate has faced pressure from biotech funding headwinds, so any signs of leasing recovery carry outsized significance. If rate cut expectations solidify later this year, REIT valuations broadly could re-rate higher, providing an additional macro tailwind for ARE.

RISKS

Signal quality scores just 50 out of 100, flagging this as an average setup — not an early-in-move entry. That's the primary concern. Missing fundamental data (P/E, EPS, 52-week range, Beta) limits full context on valuation and historical positioning. Volume at 1.62x average is decent but not decisive. Life science REITs remain exposed to continued weakness in biotech tenant demand and potential lease non-renewals. If broader rates spike again, real estate sector rotation could reverse fast. A close back below $53.29 would undermine the breakout thesis, and a breach of $51.87 intraday low is an early warning sign.

CONVICTION: Medium — The Q2 FFO beat provides a legitimate fundamental catalyst behind the breakout, but the 50/100 signal quality score and thin fundamental data prevent higher confidence in the entry timing.

Stop: $51.35 | TP1: $57.46 | TP2: $60.05

Risk/Reward: 1:1.74

AlertEdge.io — Signals. Clarity. Edge.

This is not financial advice. Trade at your own risk.